AQQRF (Aquarius Surgical Technologies) Research & Development: $0.00 Mil (TTM As of Dec. 2025)


What is Aquarius Surgical Technologies Research & Development?

Aquarius Surgical Technologies AQQRF Research & Development is $0.00 Mil as of Dec. 2025. The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Aquarius Surgical Technologies's Research & Development for the three months ended in Dec. 2025 was $0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil.

Aquarius Surgical Technologies  (OTCPK:AQQRF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Aquarius Surgical Technologies Research & Development Related Terms

Aquarius Surgical Technologies Research & Development Historical Data

* Premium members only.

The historical data trend for Aquarius Surgical Technologies's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aquarius Surgical Technologies Research & Development Chart

Aquarius Surgical Technologies Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Aquarius Surgical Technologies Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Aquarius Surgical Technologies Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.00 Mil mean?
Aquarius Surgical Technologies (AQQRF) has a Research & Development of $0.00 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Aquarius Surgical Technologies and its competitors.
Is Aquarius Surgical Technologies' Research & Development too high?
Aquarius Surgical Technologies' current Research & Development is $0.00 Mil.
How does Aquarius Surgical Technologies' Research & Development compare to ABT and SYK?
Aquarius Surgical Technologies' Research & Development of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Aquarius Surgical Technologies and its competitors. Aquarius Surgical Technologies's current Research & Development is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aquarius Surgical Technologies stock overvalued right now?
Aquarius Surgical Technologies (AQQRF) has a current Research & Development of $0.00 Mil. The current Research & Development is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Aquarius Surgical Technologies (AQQRF), the current Research & Development is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aquarius Surgical Technologies Business Description

Other Exchanges ASTI:Canada
Address 89 Scollard Street, Toronto, ON, CAN, M5R 1G4
Aquarius Surgical Technologies Inc is engaged in the development, sale, distribution, marketing, and exploitation of laser-driven technologies for use in surgical environments. Through its subsidiary, the company operates as an international distributor, service, and support organization providing integrated laser-based solutions across multiple medical disciplines. These disciplines include urology, gynecology, ophthalmology, thoracic, ENT, cardiovascular, and neurosurgery, many of which are now considered the standard of care for treatment. Geographically, the company generates maximum revenue from the sale of medical devices in the United States, and also has its presence in Canada.